PEEL-224、长春新碱和替莫唑胺治疗儿科实体瘤 (PEEL-224)
新型拓扑异构酶 I 抑制剂 PEEL-224 作为单药并与长春新碱和替莫唑胺联合治疗难治性、进行性或复发性实体瘤儿童的 1/2 期临床试验
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estimate the objective response rate (ORR) in children with refractory, progressive and relapsed NBL and rhabdomyosarcoma (RMS) treated with the RP2D of PEEL-224 in combination with vincristine and temozolomide.
研究概览
地位
详细说明
PEEL-224 will be a multi-institutional study conducted at pediatric cancer centers. Phase 1 will enroll approximately 24 subjects (maximum of 12 evaluable subjects in phase 1A and 12 evaluable subjects in phase 1B) between ages 1 to 18 years of age with a refractory, progressive or relapsed solid tumor. Phase 2 will enroll a maximum of 18 evaluable subjects with refractory, progressive or relapsed NBL and a maximum of 17 evaluable subjects with refractory, progressive or relapsed RMS. PEEL-224 will be administered at the assigned dose on days 1 and 8 of 21-day cycles as a single agent (phase 1A) or in combination with vincristine on days 1 and 8 and temozolomide on days 1-5 (phase 1B and phase 2). Subjects may continue protocol therapy for up to 24 cycles (approximately 18 months) in the absence of progressive disease or unacceptable toxicity. Subjects will be monitored with physical exams and labs on days 1 and 8 of each cycle and disease response assessments and patient reported outcome assessments will be performed after cycles 2, 4, 6, 9, 12, 18, and 24. During phase 1, PK blood samples will be drawn during cycle 1. The primary phase 1 endpoints are cycle 1 dose limiting toxicity (DLT) to define the RP2D. The primary phase 2 endpoint is best overall objective response to define the ORR.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Meghan Donnelly, MPH
- 电话号码:267-426-9343
- 邮箱:donnellymt@chop.edu
研究联系人备份
- 姓名:James Robinson, MSW, MPH
- 电话号码:215-590-2053
- 邮箱:robinsonj9@chop.edu
学习地点
-
-
California
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars-Sinai Medical Center
-
首席研究员:
- Leo Mascarhenhas, MD
-
San Francisco、California、美国、94143
- 招聘中
- University of California, San Francisco
-
首席研究员:
- Jennifer Michlitsch, MD
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Boston Children's Hospital
-
首席研究员:
- David Shulman, MD
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
首席研究员:
- David Shulman, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Children's Hospital of Philadelphia
-
接触:
- Meghan Donnelly, MPH
- 电话号码:267-426-9343
- 邮箱:donnellymt@chop.edu
-
首席研究员:
- Jacquelyn Crane, MD
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- Texas Children's Hospital
-
首席研究员:
- Jennifer Foster, MD
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- 招聘中
- University of Utah Hospital
-
首席研究员:
- Matthew Dietz, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Age:
- Phase 1: Age greater than or equal to 1 year and less than or equal to18 years
- Phase 2 Neuroblastoma (NBL) cohort: Age greater than or equal to 1 year and less than or equal to 30 years
- Phase 2 Rhabdomyosarcoma (RMS) cohort: Age greater than or equal to 1 year and less than or equal to18 years
-
Diagnosis of:
- Phase 1: Refractory, progressive or relapsed non-central nervous system (CNS) solid tumors who have received at least 1 line of upfront therapy. Patients must have had histologic verification of their malignancy at original diagnosis or relapse
- Phase 2: Refractory, progressive or relapsed neuroblastoma (NBL) or rhabdomyosarcoma (RMS) who have received at least 1 line of upfront therapy. Patients must have had histologic verification of their malignancy at original diagnosis or relapse.
-
Disease status:
- Phase 1: evaluable or measurable disease
- Phase 2, subjects with Neuroblastoma (NBL): evaluable or measurable disease by International Neuroblastoma Response Criteria (INRC); subjects with only bone marrow disease are not eligible
- Phase 2, subjects with rhabdomyosarcoma (RMS): measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)1.1.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (age greater than 16 years) or Lansky Performance Status of at least 60 (age less than 16 years).
-
Females of childbearing potential must have a negative urine/serum pregnancy test.
-
Adequate bone marrow function
Hematologic requirements for all subjects on phase 1 and subjects on phase 2 without malignant infiltration of the bone marrow:
- Absolute neutrophil count (ANC) greater than or equal to 750/mm3 (greater than or equal to 7 days since last dose of short acting myeloid growth factor medications (e.g. filgrastim) and greater than or equal to 14 days since last dose of long-acting myeloid medications (e.g. peg-filgrastim)
- Platelet count ≥ 75,000 mm3 (greater than or equal to 14 days since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days)
- Not refractory to packed red blood cell transfusions
Hematologic requirements for subjects on phase 2 with malignant infiltration of the bone marrow:
- Absolute neutrophil count (ANC) greater than or equal to 500/mm3 (greater than or equal to 7 days since last dose of short acting myeloid growth factor medications (e.g. filgrastim) and greater than or equal to 14 days since last dose of long-acting myeloid medications (e.g. peg-filgrastim))
- Platelet count greater than or equal to 50,000/mm3 (greater than or equal to 14 days since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days)
- Not refractory to packed red blood cell transfusions
- Patients on phase 2 with malignant infiltration of the bone marrow will not be evaluable for hematologic toxicity.
-
Adequate renal function as evidenced by creatinine clearance as calculated by the Schwartz equation (see below), radioisotope glomerular filtration rate (GFR) greater than or equal to 70 mL/min/1.73 m2, or maximum serum creatinine as below:
Age Maximum Serum Creatinine (mg/dL)
Male Female 1 to less than 2 years 0.6 0.6 2 to less than 6 years 0.8 0.8 6 to less than 10 years 1 1 10 to less than 13 years 1.2 1.2 13 to less than 16 years 1.5 1.4 greater than 16 years 1.7 1.4 Threshold derived from the Schwartz formula for estimating glomerular filtration rate (GFR) (Schwartz et al., J.Peds, 106:522,1985) utilizing child length and stature data published by the CDC The Schwartz equation for subjects less than 18 years of age: eGFR (mL/min/1.73 m2) = 0.413 x [height (cm)/serum creatinine (mg/dL)]
-
Adequate liver function
- Aspartate Aminotransferase (AST/SGOT): less than or equal to 3 times the upper limit of normal (ULN) or less than or equal to 5 the upper limit of normal if attributable to disease involvement. For the purpose of this study, the upper limit of normal (ULN) for Aspartate Aminotransferase (AST) is 50 U/L.
- Alanine Aminotransferase (ALT/SGPT): less than or equal to 3 times the ULN or less than or equal to 5 the upper limit of normal if attributable to disease involvement. For the purpose of this study, the upper limit of normal (ULN) for Alanine Aminotransferase (ALT) is 45 U/L.
- Total bilirubin: less than or equal to 1.5 times the upper limit of normal with the exception of patients with Gilbert's syndrome who must have bilirubin less than 3X institutional upper limit of normal (ULN).
-
Prior Therapy: Patients must have had resolution of acute toxic effects of prior therapy to grade less than or equal to 1 according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 5.0 except organ function as noted above, adverse events (AE) that are considered clinically non-significant (i.e. alopecia), or controlled on supportive care (i.e. nausea/vomiting, hypothyroidism). Patients must meet the following minimum washout periods prior to enrollment:
-
Myelosuppressive chemotherapy: At least 14 days after the last dose of myelosuppressive chemotherapy
-
Small molecule targeted therapy: At least 7 days following the last dose of a small molecule targeted agent.
-
Antibody therapy: At least 21 days following the last dose of antibody including anti-GD2 monoclonal antibody.
-
Cellular therapy: At least 42 days following completion of a cellular therapy agent (e.g. modified T cells, NK cells, dendritic cells)
-
Autologous hematopoietic stem cell transplant and stem cell boost: Subjects must be at least 60 days from day 0 of an autologous stem cell transplant or stem cell boost.
-
Myeloid growth factors: At least 7 days following short-acting myeloid growth factor (e.g. filgrastim) and at least 14 days following the last dose of long-acting myeloid growth factor (e.g. peg-filgrastim)
-
Thrombopoietin receptor agonists: At least 14 days following last dose of thrombopoietin receptor agonist such as romiplostim
-
Interleukins, interferons, and cytokines (other than hematopoietic growth factors): At least 21 days following the completion of interleukins, interferon, or cytokines, including IL-2
-
Radiotherapy:
- At least 14 days after limited field radiation therapy;
- At least 90 days after total body irradiation, craniospinal radiotherapy; or radiation to greater than 50% of pelvis;
- At least 42 days must have elapsed if other substantial BM radiation.
-
Radiopharmaceutical therapy (e.g. radiolabeled antibody, 131I- MIBG): At least 42 days after radiopharmaceutical therapy
-
Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Biopsy, CNS shunt placement/revision, and central line placement/removal are not considered major.
-
Strong CYP1A2 and/or CYP3A4 inhibitors and/or inducers: At least 14 days following use of a strong CYP1A2 and/or CYP3A4 inhibitor and/or inducer. See Appendix 1 for examples. (Note that levofloxacin is permitted when clinically indicated)
-
-
Prior treatment with irinotecan and/or temozolomide is permitted.
-
Female patients of reproductive potential must agree to use a highly effective contraceptive method for the duration of study therapy and for at least six months after the final dose of PEEL-224. Males of reproductive potential with a female partner of child-bearing potential must use a highly effective for the duration of the study and for at least six months after the final dose of PEEL-224.
-
Subjects must agree to use sun protective measures while receiving treatment and for 4 weeks after the last dose of PEEL-224
-
Parental/guardian permission (informed consent) and if appropriate, child assent.
Exclusion Criteria:
- Prior treatment with PEEL-224.
- Subjects receiving any other anti-cancer agents.
- Subjects with primary central nervous system (CNS) solid tumors or central nervous system (CNS) metastatic disease.
- Subjects with prior allogeneic stem cell or solid organ transplantation.
- Pregnant or lactating females.
- Subjects with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening).
- Subjects with symptomatic congestive heart failure.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:PEEL-224
Phase 1A will test the safety, tolerability and PK profile of PEEL-224 as a single agent in pediatric patients with refractory, progressive and relapsed solid tumors. |
PEEL-224 (PEG-[SN22]4) is a novel topoisomerase I inhibitor |
|
实验性的:PEEL-224, Vincristine, and Temozolomide
Phase 1B will test the safety, tolerability and pharmacokinetic profile of PEEL-224 in combination with vincristine and temozolomide in pediatric subjects with refractory, progressive and relapsed solid tumors. Phase 2 will preliminary evaluate the activity profile of PEEL-224 in combination with vincristine and temozolomide in pediatric patients with refractory, progressive and relapsed NBL and RMS. |
PEEL-224 (PEG-[SN22]4) is a novel topoisomerase I inhibitor Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available. Temozolomide is an alkylating agent which is approved by the FDA and is commercially available. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1A and Phase 1B: Number of participants who experience a dose limiting toxicity (DLT)
大体时间:1 month
|
The observation of a dose-limiting toxicity (DLT) or lack of observation of DLT in the period between treatment initiation up to initiation of cycle 2 treatment. A dose limiting toxicity (DLT) describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. |
1 month
|
|
Phase 2 Neuroblastoma Cohort (NBL): Number of paricptants who achieve a complete response (CR), partial response (PR), or minor response (MR)
大体时间:2 years
|
Objective response as assessed by the Revised International Neuroblastoma Response Criteria (INRC). Response is defined as complete response (CR), partial response (PR) or minor response (MR), using best response measured at any point prior to local control. |
2 years
|
|
Phase 2 Rhabdomyosarcoma (RMS) Cohort: Number of participants who achieve a complete response (CR) or partial response (PR)
大体时间:2 years
|
Objective response as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Response is defined as complete response (CR) or partial response (PR), using best response measured at any point prior to local control. |
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of subjects with an Adverse Event (AE) of greater than or equal to grade 3 at least possibly attributable to study treatment
大体时间:30 days after last dose
|
Adverse Events (AEs) will be graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
30 days after last dose
|
|
Area under the plasma-concentration-time-curve of PEEL-224
大体时间:1 month
|
To characterize the pharmacokinetic (PK) profile of free SN22 and SN22 bound to PEG (PEEL-224) |
1 month
|
|
Number of participants demonstrating anti-tumor activity of PEEL-224
大体时间:2 years
|
To preliminarily evaluate antitumor activity of PEEL-224 by estimating event-free survival (EFS) |
2 years
|
|
Number of participants demonstrating anti-tumor activity of the combination of PEEL-224, vincristine and temozolomide
大体时间:2 years
|
To preliminarily evaluate antitumor activity of the combination of PEEL-224, vincristine and temozolomide by estimating event-free survival (EFS ) |
2 years
|
合作者和调查者
调查人员
- 首席研究员:Jacquelyn Crane, MD、Children's Hospital of Philadelphia
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 24-022741
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.